Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more
Clarity Pharmaceuticals Ltd (CLRPF) - Total Assets
Latest total assets as of June 2025: $101.17 Million USD
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CLRPF) holds total assets worth $101.17 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Clarity Pharmaceuticals Ltd - Total Assets Trend (2022–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Clarity Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Clarity Pharmaceuticals Ltd's total assets of $101.17 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clarity Pharmaceuticals Ltd's current assets represent 99.4% of total assets in 2025, a decrease from 99.7% in 2022.
- Cash Position: Cash and equivalents constituted 47.1% of total assets in 2025, down from 55.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Clarity Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Clarity Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Clarity Pharmaceuticals Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Clarity Pharmaceuticals Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Clarity Pharmaceuticals Ltd is currently not profitable relative to its asset base.
Clarity Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.69 | 19.05 | 11.45 |
| Quick Ratio | 9.69 | 19.05 | 11.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $90.23 Million | $ 145.97 Million | $ 81.64 Million |
Clarity Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Clarity Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.15 |
| Latest Market Cap to Assets Ratio | 2.20 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | $101.17 Million |
| Market Capitalization | $222.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Clarity Pharmaceuticals Ltd's assets at a significant premium ( 2.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Clarity Pharmaceuticals Ltd's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clarity Pharmaceuticals Ltd (2022–2025)
The table below shows the annual total assets of Clarity Pharmaceuticals Ltd from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $101.17 Million | -34.57% |
| 2024-06-30 | $154.63 Million | +101.09% |
| 2023-06-30 | $76.90 Million | -22.97% |
| 2022-06-30 | $99.82 Million | -- |